Table 1.

Patient characteristics (n = 161)

		Surgical margin
Characteristics	All (n = 161) (%)	< 1 mm (n = 28) (%)	≥ 1 mm, <  2 mm (n = 21) (%)	≥ 2 mm (n = 112) (%)	P
Age, year
Median (range)	47.4 (25.4–87.3)	51.7 (27.6–87.3)	46.4 (25.4–68.5)	46.9 (27.6–74.7)
Mean ± SD	48.1 ± 11.0	51.7 ± 13.5	46.3 ± 10.1	47.5 ± 10.4
<  50	96 (59.6)	13 (46.4)	12 (57.1)	71 (63.4)	0.254
≥ 50	65 (40.4)	15 (53.6)	9 (42.9)	41 (36.6)
Tumour size
T1 (≤ 2 cm)	18 (11.2)	3 (10.7)	1 (4.8)	14 (12.5)	0.782
T2 (>  2 cm, ≤ 5 cm)	132 (82.0)	24 (85.7)	18 (85.7)	90 (80.4)
T3 (>  5 cm)	11 (6.8)	1 (3.6)	2 (9.5)	8 (7.1)
Lymph node status
Negative	34 (21.1)	6 (21.4)	5 (23.8)	23 (20.5)	0.944
Positive	127 (78.9)	22 (78.6)	16 (76.2)	89 (79.5)
Histological type
IDC	145 (90.1)	22 (78.6)	19 (90.5)	104 (92.9)	0.152
IDC + DCIS	12 (7.5)	4 (14.3)	1 (4.8)	7 (6.2)
Others	4 (2.5)	2 (7.1)	1 (4.8)	1 (0.9)
Histological grade
in situ	2 (1.3)	1 (3.6)	1 (5.0)	0 (0)	0.173
I	17 (11.3)	4 (14.3)	1 (5.0)	12 (11.8)
II	77 (51.3)	16 (57.1)	13 (65.0)	48 (47.1)
III	54 (36.0)	7 (25.0)	5 (25.0)	42 (41.2)
Missing	11	0	1	10
Intrinsic subtype
Luminal	53 (32.9)	9 (32.1)	11 (52.4)	33 (29.5)	0.379
Luminal HER2	41 (25.5)	8 (28.6)	3 (14.3)	30 (26.8)
HER2	21 (13.0)	5 (17.9)	3 (14.3)	13 (11.6)
TNBC	46 (28.6)	6 (21.4)	4 (19.0)	36 (32.1)
Chemotherapy
Anthracycline-based	33 (20.5)	5 (17.9)	7 (33.3)	21 (18.8)	0.427
Taxane-based	14 (8.7)	2 (7.1)	2 (9.5)	10 (8.9)
Combined anthracycline and taxane	65 40.4)	10 (35.7)	7 (33.3)	48 (42.9)
HER2 targeting agent contained	46 (28.6)	9 (32.1)	5 (23.8)	32 (28.6)
Others	3 (1.9)	2 (7.1)	0 (0)	1 (0.9)
Follow-up, month
Median (range)	34.7 (5.3–118.9)	23.5 (5.3–105.5)	39.3 (7.7–105.6)	35.8 (6.9–118.9)
Mean ± SD	44.9 ± 31.8	36.1 ± 29.5	49.3 ± 34.2	46.2 ± 31.9